BioCentury
ARTICLE | Company News

Bio Fluorescent Technologies Inc., Immune Network Research Ltd. deal

October 28, 1996 8:00 AM UTC

BFTI said it intends to merge with IMM, a developer of monoclonal antibody-based products and vaccines to treat AIDS and other immune system disorders. BFTI, a developer of diagnostics for viral diseases, would issue an undisclosed amount of securities to IMM. BFTI shareholders would own 40 percent of the company, which would retain the BFTI name, and IMM shareholders would own 60 percent. BFTI said it had $350,000 in cash. ...